Specific Diagnostics has developed an in vitro diagnostic system based upon a unique, patented metabolomic signature technology that enables rapid detection and identification of microorganisms as they grow in culture.
Its first commercial application applies this fundamental new capability to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as isolate dilutions.
The Reveal Rapid AST system addresses the clinical need for rapid susceptibility testing directly from positive blood cultures, while at the same time reducing the cost per test. The Reveal Rapid AST system delivers phenotypic antimicrobial susceptibility testing with MIC results for a large panel of antimicrobials in an average of five hours, allowing same-shift guidance for antimicrobial therapy.